Patents by Inventor Timothy Billiar

Timothy Billiar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Time window-based platform for the rapid stratification of blunt trauma patients into distinct outcome cohorts
    Patent number: 11854701
    Abstract: Provided herein are methods for segregating trauma, e.g., blunt trauma, patients into different cohorts based on risk of multiple organ dysfunction syndrome using patient data obtained within a short time window following injury. The methods are useful in providing treatment to trauma patients, and for separating trauma patients into cohorts.
    Type: Grant
    Filed: September 13, 2021
    Date of Patent: December 26, 2023
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Gregory M. Constantine, Timothy Billiar, Qi Mi, Rami Namas, Lukas Schimunek, Yoram Vodovotz
  • Time Window-Based Platform for the Rapid Stratification of Blunt Trauma Patients into Distinct Outcome Cohorts
    Publication number: 20220215963
    Abstract: Provided herein are methods for segregating trauma, e.g., blunt trauma, patients into different cohorts based on risk of multiple organ dysfunction syndrome using patient data obtained within a short time window following injury. The methods are useful in providing treatment to trauma patients, and for separating trauma patients into cohorts.
    Type: Application
    Filed: September 13, 2021
    Publication date: July 7, 2022
    Inventors: Gregory M. Constantine, Timothy Billiar, Qi Mi, Rami Namas, Lukas Schimunek, Yoram Vodovotz
  • Methods of treating conditions involving elevated inflammatory response
    Patent number: 11179412
    Abstract: A method of treating a patient having an elevated inflammatory response, such as an elevated Type I interferon response, is provided. The method can be used to treat sepsis. The method comprises administering to a patient having an elevated inflammatory response, an inhibitor of anaplastic lymphoma kinase (ALK inhibitors) or expression of ALK, in an amount effective to treat the elevated inflammatory response.
    Type: Grant
    Filed: December 4, 2018
    Date of Patent: November 23, 2021
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Daolin Tang, Timothy Billiar, Ling Zeng
  • Methods of Treating Conditions Involving Elevated Inflammatory Response
    Publication number: 20190167710
    Abstract: A method of treating a patient having an elevated inflammatory response, such as an elevated Type I interferon response, is provided. The method can be used to treat sepsis. The method comprises administering to a patient having an elevated inflammatory response, an inhibitor of anaplastic lymphoma kinase (ALK inhibitors) or expression of ALK, in an amount effective to treat the elevated inflammatory response.
    Type: Application
    Filed: December 4, 2018
    Publication date: June 6, 2019
    Inventors: Daolin Tang, Timothy Billiar, Ling Zeng
  • Time Window-Based Platform for the Rapid Stratification of Blunt Trauma Patients into Distinct Outcome Cohorts
    Publication number: 20180322956
    Abstract: Provided herein are methods for segregating trauma, e.g., blunt trauma, patients into different cohorts based on risk of multiple organ dysfunction syndrome using patient data obtained within a short time window following injury. The methods are useful in providing treatment to trauma patients, and for separating trauma patients into cohorts.
    Type: Application
    Filed: May 4, 2018
    Publication date: November 8, 2018
    Inventors: Gregory M. Constantine, Timothy Billiar, Qi Mi, Yoram Vodovotz, Rami Namas, Lukas Schimunek
  • USE OF HMGB1 FOR PROTECTION AGAINST ISCHEMIA REPERFUSION INJURY
    Publication number: 20080004207
    Abstract: Methods and compositions are disclosed for protecting an organ or tissue from inflammation and organ injury following ischemia, reperfusion, and trauma through the administration of an HMGB1 protein within a time period sufficient to protect the organ or tissue from injury.
    Type: Application
    Filed: February 6, 2007
    Publication date: January 3, 2008
    Applicants: University of pittsburgh of the Commonwealth System of Higher Education, The Feinstein Institute for Medical Research
    Inventors: Allan Tsung, Timothy Billiar, Mitchell Fink, Kevin Tracey